These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17687273)

  • 1. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.
    Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen K; Neuvonen PJ; Laine K
    Clin Pharmacol Ther; 2008 Feb; 83(2):342-8. PubMed ID: 17687273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
    Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
    Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
    Levin GM; Nelson LA; DeVane CL; Preston SL; Eisele G; Carson SW
    Psychopharmacol Bull; 2001; 35(2):62-71. PubMed ID: 12397887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of voriconazole on the pharmacokinetics of diclofenac.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Laine K
    Fundam Clin Pharmacol; 2007 Dec; 21(6):651-6. PubMed ID: 18034666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of venlafaxine on the pharmacokinetics of alprazolam.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    Psychopharmacol Bull; 1998; 34(2):211-9. PubMed ID: 9641003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.
    Whyte EM; Romkes M; Mulsant BH; Kirshne MA; Begley AE; Reynolds CF; Pollock BG
    Int J Geriatr Psychiatry; 2006 Jun; 21(6):542-9. PubMed ID: 16642541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
    Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
    Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
    Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
    Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
    Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
    Preskorn SH
    J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen.
    Hynninen VV; Olkkola KT; Leino K; Lundgren S; Neuvonen PJ; Rane A; Valtonen M; Vyyryläinen H; Laine K
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1967-72. PubMed ID: 16723553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
    Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
    Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.
    Kandasamy M; Srinivas P; Subramaniam K; Ravi S; John J; Shekar R; Srinivas N; Thangam S
    Eur J Clin Pharmacol; 2010 Sep; 66(9):879-87. PubMed ID: 20446083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of venlafaxine on the pharmacokinetics of risperidone.
    Amchin J; Zarycranski W; Taylor KP; Albano D; Klockowski PM
    J Clin Pharmacol; 1999 Mar; 39(3):297-309. PubMed ID: 10073330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole and fluconazole increase the exposure to oral diazepam.
    Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of venlafaxine extended release 75  mg and desvenlafaxine 50  mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
    Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
    Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population.
    Fukuda T; Nishida Y; Zhou Q; Yamamoto I; Kondo S; Azuma J
    Eur J Clin Pharmacol; 2000 May; 56(2):175-80. PubMed ID: 10877013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.